AstraZeneca plans to nearly double sales to $80 billion in 2030

British pharmaceutical giant AstraZeneca said on Tuesday that it aims to reach sales of $80 billion by 2030, nearly double from $45.8 billion in 2023.

British pharmaceutical giant AstraZeneca said on Tuesday that it aims to achieve sales of US$80 billion by 2030, nearly double from US$45.8 billion in 2023.
The company said it plans to launch 20 new drugs by 2030 to achieve its new total revenue target.
Investment bank Jefferies previously predicted that AstraZeneca\’s annual sales will exceed US$70 billion by 2031.
Astra set the target ahead of its first investor day event in 10 years.
The company\’s CEO Suboko said that he hopes to make AstraZeneca stand out in the highly competitive cancer drug market.

Like (0)
Previous May 21, 2024 4:04 pm
Next May 21, 2024 4:04 pm

Related posts

  • Nordisk fell 1.1% in premarket as the U.S. Senate launches investigation into Novo Nordisk\’s GLP-1 drug pricing

    Gelonghui, April 25 | Nord Nordisk (NVO.US) U.S. stocks fell 1.1% before the market opened, to US$124.74. On the news, U.S. Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders said on Wednesday that the committee is launching an investigation into Novo Nordisk\’s pricing. In a letter sent to Novo Nordisk\’s CEO on Wednesday, Sanders asked Novo Nordisk to provide \”internal communications about the U.S. pricing of the drug\” and explain why Ozempic and Wegovy have the same ingredient (semaglutide). ), Wegovy’s pricing is obviously more expensive. Sanders stressed that the price of GLP-1 drugs \”must come down\” so that consumers can afford them and the government doesn\’t go bankrupt by reimbursing them.

    US stock market April 25, 2024
  • Gift Nifty signals flat-to-positive opening; low participation expected

    As we approach the weekend, domestic markets are anticipated to open flat on Friday. It’s worth noting that market participation is expected to remain low, primarily due to the long weekend holidays. This is because the market will be closed on Monday for local polling related to the general election, a factor that could influence trading volumes and market dynamics.

    US stock market May 17, 2024
  • Mid-day updates: Sensex surges over 2,300 points, Nifty crosses 23,200 on high optimism

    The Indian stock market witnessed a significant surge today. The BSE Sensex was up by 3.13 per cent, or 2,292.14 points, to 76,244.18, while the NSE Nifty was at 23,221, up by 3.07 per cent, or 690.75 points, at 12.40 pm. This was driven by optimism fueled by exit poll predictions of a victory for the NDA government.

    US stock market June 3, 2024
  • China Council for International Cooperation on Environment and Development 2024 Roundtable was held in Haikou

    On April 25, the China Council for International Cooperation on Environment and Development (hereinafter referred to as CCICED) 2024 Roundtable was held in Haikou City, Hainan Province. The theme of the conference is \”Blue Economy Helps Beautiful Hainan\”. Secretary of the Hainan Provincial Party Committee Feng Fei, Governor Liu Xiaoming, Vice Minister of the Ministry of Ecology and Environment and Secretary-General of the CCICED Zhao Yingmin, Deputy Executive Director of the United Nations Environment Program and Assistant Secretary-General of the United Nations Murema attended the meeting and delivered speeches.

    US stock market April 25, 2024
  • Nordisk fell 1.1% in premarket as the U.S. Senate launches investigation into Novo Nordisk\’s GLP-1 drug pricing

    Gelonghui, April 25 | Nord Nordisk (NVO.US) U.S. stocks fell 1.1% before the market opened, to US$124.74. On the news, U.S. Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders said on Wednesday that the committee is launching an investigation into Novo Nordisk\’s pricing. In a letter sent to Novo Nordisk\’s CEO on Wednesday, Sanders asked Novo Nordisk to provide \”internal communications about the U.S. pricing of the drug\” and explain why Ozempic and Wegovy have the same ingredient (semaglutide). ), Wegovy’s pricing is obviously more expensive. Sanders stressed that the price of GLP-1 drugs \”must come down\” so that consumers can afford them and the government doesn\’t go bankrupt by reimbursing them.

    US stock market April 25, 2024
  • Shanshi Network Technology: Loss of 75.4048 million yuan in the first quarter of 2024

    CSI Intelligent Financial Information Shanshi Network Technology (688030) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 151 million yuan, a year-on-year increase of 4.49%; net profit attributable to the parent company was a loss of 75.4048 million yuan, a loss of 87.4564 million yuan in the same period last year; a loss after deducting non-net profits was 75.7863 million yuan, a loss in the same period last year 91.9258 million yuan; the net cash flow generated from operating activities was -10.7085 million yuan, compared with -12.6281 million yuan in the same period last year; during the reporting period, Shanshi Network\’s basic earnings per share was -0.4184 yuan, and the weighted average return on net assets was -7.26%.

    US stock market April 25, 2024